Anti‐inflammatory properties of conditioned medium from human Wharton’s jelly mesenchymal stem cells

Rizal Azis; Wahyu Widowati; Rimonta Febby Gunanegara; Hanna Sari Widya Kusuma; Dwi Nur Triharsiwi; Dhanar Septyawan Hadiprasetyo; Marisca Evalina Gondokesumo; Nicholas Mars

doi:10.22146/ijbiotech.107035

Anti‐inflammatory properties of conditioned medium from human Wharton’s jelly mesenchymal stem cells

https://doi.org/10.22146/ijbiotech.107035

Rizal Azis^(1*), Wahyu Widowati⁽²⁾, Rimonta Febby Gunanegara⁽³⁾, Hanna Sari Widya Kusuma⁽⁴⁾, Dwi Nur Triharsiwi⁽⁵⁾, Dhanar Septyawan Hadiprasetyo⁽⁶⁾, Marisca Evalina Gondokesumo⁽⁷⁾, Nicholas Mars⁽⁸⁾

(1) Biomedical Engineering, Department of Electrical Engineering, Faculty of Engineering, Universitas Indonesia, Depok 16424, Indonesia; Biomolecular and Biomedical Research Center, Aretha Medika Utama, Bandung 40163, Indonesia
(2) Faculty of Medicine, Maranatha Christian University, Bandung 40164, Indonesia
(3) Faculty of Medicine, Maranatha Christian University, Bandung 40164, Indonesia
(4) Biomolecular and Biomedical Research Center, Aretha Medika Utama, Bandung 40163, Indonesia
(5) Biomolecular and Biomedical Research Center, Aretha Medika Utama, Bandung 40163, Indonesia
(6) Biomolecular and Biomedical Research Center, Aretha Medika Utama, Bandung 40163, Indonesia; Faculty of Pharmacy, Universitas Jenderal Achmad Yani, Cimahi 40525, Indonesia
(7) Faculty of Pharmacy, University of Surabaya, Surabaya 60293, Indonesia
(8) Department of Biology, Faculty of Mathematics and Science Education, Jakarta State University, East Jakarta 13220, Indonesia
(*) Corresponding Author

Abstract

Acute respiratory distress syndrome (ARDS) is a critical respiratory dysfunction triggered by intense in‐ flammation, microvascular damage, and increased epithelial and pulmonary vascular permeability. Human Wharton’s jelly mesenchymal stem cells (hWJMSCs) possess regenerative and anti‐inflammatory activities through the cytokines, chemokines, and growth factor secretion. The development of anti‐inflammatory agents derived from hWJMSCs has become one of the therapeutic solutions. Instead of direct cell use of hWJMSCs, their conditioned medium (CM) provides a cell‐free approach that delivers bioactive factors while minimizing the risks associated with stem cell transplantation. This study aims to measure the levels of vascular endothelial growth factor‐α (VEGF‐α), epidermal growth factor‐β (EGF‐β), interleukin‐10 (IL‐10), and hepatocyte growth factor (HGF) in CM‐hWJMSCs under non‐starvation and starvation conditions (24, 48 and 72 hours) using ELISA. The anti‐inflammatory potential of these factors was then analyzed through molecular docking with pro‐inflammatory cytokines. VEGF‐α, EGF‐β, IL‐10 and HGF levels were measured across all conditions. VEGF‐α ranged from 2590.37 to 3613.92 ng/mg protein; EGF‐β 347.01–504.43 ng/mg; IL‐10 302.59–729.28 pg/mg; and HGF 1747.20–2903.52 ng/mg. The molecular docking revealed strong binding between VEGF‐α, EGF‐β, IL‐10 and HGF with pro‐inflammatory cytokines, namely IL‐1β, IL‐6 and TNF‐α. VEGF‐α had the strongest bond with TNF‐α (–1162.3 kJ/mol), while EGF‐β formed the most hydrophobic and hydrogen interactions. The findings suggest that CM‐hWJMSCs, enriched with anti‐inflammatory and regenerative cytokines, may serve as a promising candidate for modulating the inflammatory pathways involved in ARDS pathogenesis. Longer starvation increased the secretion of VEGF‐α, EGF‐β, IL‐10 and HGF. These factors are known to promote angiogenesis, regulate immune responses, and protect against epithelial injury, thereby supporting the anti‐inflammatory and regenerative potential of hWJMSCs‐CM for ARDS therapy.

Keywords

Anti‐inflammatory properties; ARDS; Conditioned medium; Growth factor; hWJMSCs

Full Text:

PDF

References

Bogatcheva NV, Coleman ME. 2019. Conditioned medium of mesenchymal stromal cells: a new class of therapeutics. Biochem. (Mosc). 84(11):1375–1389. doi:10.1134/S0006297919110129.

Eze FI, Uzor PF, Ikechukwu P, Obi BC, Osadebe PO. 2019. In vitro and in vivo models for antiinflammation: an evaluative review. INNOSC Theranostics Pharmacol. Sci. 2(2):3–15. doi:10.36922/itps.v2i2.775.

Ferenczy GG, Kellermayer M. 2022. Contribution of hydrophobic interactions to protein mechanical stability. Comput. Struct. Biotechnol. J. 20:1946–1956. doi:10.1016/j.csbj.2022.04.025.

Gnecchi M, Danieli P, Malpasso G, Ciuffreda MC. 2016. Paracrine mechanisms of mesenchymal stem cells in tissue repair. Methods Protoc. 1416:123–146. doi:https://doi.org/10.1007/9781493935840_7.

Hwang OK, Woock Y, Jin N, Hong T. 2020. Hypoxia pretreatment promotes chondrocyte differentiation of human adiposederived stem cells via vascular endothelial growth factor. Tissue Eng. Regen. Med. 17:335– 350. doi:10.1007/s13770020002655.

Jiménez-Valerio G, Casanovas O. 2017. Angiogenesis and metabolism: entwined for therapy resistance. Trends Cancer 3(1):10–18. doi:10.1016/j.trecan.2016.11.007.

Kim H, Lee S, Lee S, Oh BJ, Kim JH, Kim JA, et al. 2019. A subset of paracrine factors as efficient biomarkers for predicting vascular regenerative efficacy of mesenchymal stromal/stem cells. Stem Cells 37(1):77– 88. doi:10.1002/stem.2920.

Li X, Ma X. 2020. Acute respiratory failure in COVID19: is it “typical” ARDS? Crit. Care 24(1):1–5.

Liu Z, Liu D, Wang Z, Zou Y, Wang H, Li X, et al. 2022. Association between inflammatory biomarkers and acute respiratory distress syndrome or acute lung injury risk: a systematic review and metaanalysis. Wien Klin. Wochenschr. 134(12):24–38. doi:10.1186/s13054020029119.

Loy H, Kuok DIT, Hui KPY, Choi MHL, Yuen W, Nicholls JM, et al. 2019. Therapeutic implications of human umbilical cord mesenchymal stromal cells in attenuating influenza A (H5N1) virusassociated acute lung injury. J. Infect. Dis. 219(2):186–196. doi:10.1093/infdis/jiy478.

Matsuda M, Huh Y, Rong R. 2019. Roles of inflammation, neurogenic inflammation, and neuroinflammation in pain. J. Anesth. 33(1):131–139. doi:10.1007/s00540 01825794.

Moradinasab S, Pourbagheri-Sigaroodi A, Zafari P, Ghaffari SH, Bashash D. 2021. Mesenchymal stromal/stem cells and MSCderived extracellular vesicles in COVID19-induced ARDS: mechanisms of action, research progress, challenges, and opportunities. Int. Immunopharmacol. 97:107694. doi:10.1016/j.intimp.2021.107694.

Noverina R, Widowati W, Ayuningtyas W, Rinendyaputri R, Rilianawati R, Faried A. 2019. Growth factors profile in conditioned medium human adipose tissuederived mesenchymal stem cells (CMhATMSCs). Clin. Nutr. Exp. 24:34–44. doi:10.1016/j.yclnex.2019.01.002.

Perreau M, Suf M, Marques-Vidal P, Wiedemann A, Levy Y, Laouénan C, et al. 2021. The cytokines HGF and CXCL13 predict the severity and mortality in COVID19 patients. Nat. Commun. 12(1):1–10. doi:10.1038/s41467021251915.

Püschel F, Favaro F, Redondo-Pedraza J, Lucendo E, Iurlaro R. 2020. Starvation and antimetabolic therapy promote cytokine release and recruitment of immune cells. Proc. Natl. Acad. Sci. U. S. A. 117(18):9932– 9941. doi:10.1073/pnas.1913707117.

Sagaradze G, Grigorieva O, Nimiritsky P, Basalova N, Kalinina N, Akopyan Z, et al. 2019. Conditioned medium from human mesenchymal stromal cells: towards the clinical translation. Int. J. Mol. Sci. 20(7):1656. doi:10.3390/ijms20071656.

Ting H, Dilley RJ. 2018. Novel nonangiogenic role for mesenchymal stem cellderived vascular endothelial growth factor on keratinocytes during wound healing. Cytokine Growth Factor Rev. 44:1–11. doi:10.1016/j.cytogfr.2018.11.002.

Varma AK, Patil R, Das S, Stanley A, Yadav L, Sudhakar A. 2010. Optimized hydrophobic interactions and hydrogen bonding at the targetligand interface lead the pathways of drug designing. PLoS One 5(8):e12029. doi:10.1371/journal.pone.0012029.

Wang L, Li Y, Xu M, Deng Z, Zhao Y, Yang M. 2021. Regulation of inflammatory cytokine storms by mesenchymal stem cells. Front. Immunol. 12:1–14. doi:10.3389/fimmu.2021.726909.

Wang S, Mo M, Wang J, Sadia S, Shi B. 2018. Platelet-derived growth factor receptor beta identifies mesenchymal stem cells with enhanced engraftment to tissue injury and proangiogenic property. Cell. Mol. Life Sci. 75:547–561. doi:10.1007/s000180172641 7.

Widowati W, Prahastuti S, Ekayanti NLW, Munshy UZ, Kusuma HSW, Wibowo SHB, et al. 2019. Antiinflammation assay of black soybean extract and its compounds on lipopolysaccharideinduced RAW 264.7 cell. J. Phys. Conf. Ser. 1374(1). doi:10.1088/17426596/1374/1/012052.

Widowati W, Wargasetia TL, Rahardja F, Gunanegara RF, Handayani T, Kusuma HSW, et al. 2021. Potential of human Wharton’s jelly mesenchymal stem cells secretome for COVID19 adjuvant therapy candidate. IEEE Trans. Health Instrum. Meas. Nat. Sci. 2021:1– 6. doi:10.18502/ajmb.v16i4.16739.

Widowati W, Widyastuti H, Murti H, Laksmitawati DR, Maesaroh M, Sumitro SB, et al. 2016. Interleukins and VEGF secretome of human Wharton’s jelly mesenchymal stem cellsconditioned medium in different passages and oxygen tensions. Biomark. Genom. Med. 14(4):1–34.

Yao W, Shi L, Zhang Y, Dong H, Zhang Y. 2022. Mesenchymal stem/stromal cell therapy for COVID19 pneumonia: potential mechanisms, current clinical evidence, and future perspectives. Stem Cell Res. Ther. 13(1):1–13. doi:10.1186/s13287022028106.

Zhuang WZ, Lin YH, Su LJ, Wu MS, Jeng HY. 2021. Mesenchymal stem/stromal cellbased therapy: mechanism, systemic safety, and biodistribution for precision clinical applications. J. Biomed. Sci. 28:1–38. doi:10.1186/s12929021007257.

DOI: https://doi.org/10.22146/ijbiotech.107035